Developer docs
API playgroundTry for free, no card

Search company profiles

Fusion Pharmaceuticals

Full company profile

uuid000353x

Namestring
Fusion Pharmaceuticals
Legal namestring
Fusion Pharmaceuticals Inc.
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company developing next-generation targeted alpha therapeutics (TAT) for the treatment of cancer, built around actinium-225 alpha-emitting isotopes combined with proprietary Fast-Clear™ linker technology. The platform pairs medical isotopes with cancer-targeting molecules (antibodies, small molecules, centyrins) to deliver lethal double-stranded DNA breaks selectively to tumor cells while sparing healthy tissue, with three distinct mechanisms of action: direct DNA damage, bystander effect, and alpha-particle-mediated immune activation.

The company's pipeline includes FPI-2265 (lead asset, 225Ac-PSMA I&T in Phase 2 TATCIST for metastatic castration-resistant prostate cancer, including both PSMA-naïve and 177Lu-PSMA-pretreated patients), FPI-1434 (Phase 1 anti-IGF-1R radioimmunoconjugate for solid tumors with imaging analogue FPI-1547), FPI-2059 (anti-NTSR1 acquired from Ipsen for pancreatic, colorectal, and gastric cancers), and FPI-2068 (anti-EGFR/cMET co-developed with AstraZeneca, FDA IND clearance April 2023). Preclinical assets include FPI-1966 (FGFR3 for bladder cancer) and FPI-1848 (TEM-1 for sarcoma).

Fusion was founded in 2015 as a spin-out from McMaster University's Centre for Probe Development and Commercialization (CPDC), headquartered in Hamilton, Ontario, with US operations in Boston, MA. The company raised approximately $231M in equity across Series A, Series B, a CPPIB commitment, and a 2023 private placement before being acquired by AstraZeneca in June 2024 for approximately $2.4 billion. Pre-acquisition business model was research-driven with no commercial revenue; future monetization was expected through direct commercialization (specialty/hospital pharmacy distribution for short-half-life alpha radiopharmaceuticals) and strategic partnerships.

Short descriptiontext

Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted alpha therapeutics (actinium-225 radiopharmaceuticals with proprietary Fast-Clear™ linkers) for cancers including prostate, lung, and gastrointestinal tumors, now a wholly-owned AstraZeneca subsidiary.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersHamilton, Canada
HQ citystring
Hamilton
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
targeted alpha therapeutics, radiopharmaceutical development, cancer precision medicine, actinium-225 isotopes, clinical oncology pipeline
Industry3 codes
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAG
Nuclear Medicine Imaging Agents & Kits (Cold Kits/Precursors)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Targeted Alpha Therapeutics / Radiopharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Radiopharmaceutical Drug Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage company developing targeted alpha therapeutics pipeline. Revenue expected from future drug commercialization upon regulatory approval. Multiple candidates in clinical development targeting prostate cancer and solid tumors.

fusionpharma.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Fusion Pharmaceuticals develops clinical-stage targeted alpha therapeutics (TAT) that use actinium-225 alpha-emitting isotopes conjugated to tumor-targeting molecules (antibodies, small molecules) via its proprietary Fast-Clear™ linker technology. Lead asset FPI-2265 is in Phase 2 for metastatic castration-resistant prostate cancer, with additional candidates targeting IGF-1R, NTSR1, EGFR/cMET, FGFR3, and TEM-1 expressing tumors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Phase 2 TATCIST trial evaluating FPI-2265 (225Ac-PSMA I&T) in mCRPC with initial data expected in early 2024
+1 more record
Product overview1 text field

Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company developing next-generation radiopharmaceuticals as precision medicines for cancer treatment. The company's portfolio consists of multiple targeted alpha therapeutics (TAT) using actinium-225, built on its proprietary Fast-Clear linker technology platform. Key products include FPI-2265 (lead program, Phase 2 for mCRPC), FPI-1434 (Phase 1 for IGF-1R expressing solid tumors), FPI-2059 (NTSR1-targeted for solid tumors), FPI-2068 (EGFR/cMET-targeting), and several preclinical candidates (FPI-1966, FPI-1848). The Fast-Clear linker technology differentiates the platform by promoting rapid excretion of unbound isotopes to improve safety and expand the therapeutic window.

Product and service7 records
1FPI-2265 (225Ac-PSMA I&T)
CategoryTargeted Alpha Therapeutic (TAT) — Oncology Pipeline Asset
Description

Alpha-emitting radiopharmaceutical using actinium-225 conjugated to a PSMA-targeting small molecule, in Phase 2 for metastatic castration-resistant prostate cancer (mCRPC). Built on Fusion's Fast-Clear linker technology.

2FPI-1434
CategoryTargeted Alpha Therapeutic (TAT) — Oncology Pipeline Asset
Description

Targeted alpha radioimmunoconjugate consisting of anti-IGF-1R humanized monoclonal antibody, Fusion's Fast-Clear linker, a bifunctional chelate, and actinium-225. In Phase 1 for solid tumors expressing IGF-1R (non-small cell lung, prostate, sarcomas, breast).

3FPI-2059
CategoryTargeted Alpha Therapeutic (TAT) — Oncology Pipeline Asset
Description

Small-molecule targeted alpha therapy combining Ipsen's IPN-1087 NTSR1 ligand with actinium-225 for solid tumors overexpressing neurotensin receptor 1 (NTSR1), including pancreatic ductal adenocarcinoma, colorectal cancer, and gastric cancers.

4FPI-2068
CategoryTargeted Alpha Therapeutic (TAT) — Oncology Pipeline Asset
Description

Anti-EGFR/cMET alpha-particle emitting radioimmunoconjugate co-developed with AstraZeneca for cancer therapy; FDA IND cleared April 2023.

5FPI-1966
CategoryTargeted Alpha Therapeutic (TAT) — Preclinical Asset
Description

FGFR3-targeted alpha therapeutic using actinium-225; preclinical-stage asset for bladder cancer.

6FPI-1848
CategoryTargeted Alpha Therapeutic (TAT) — Preclinical Asset
Description

TEM-1-targeted alpha therapeutic using actinium-225; preclinical-stage asset for sarcoma.

7FPI-1547
CategoryCompanion Diagnostic / Imaging Agent
Description

Imaging/diagnostic analogue of FPI-1434 using indium-111 (111In) in place of actinium-225, used for patient selection and quantification of IGF-1R-expressing tumors prior to therapy.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-04-01
Description

Joint development of FPI-2068, a novel anti-EGFR/cMET alpha-particle emitting radioimmunoconjugate for cancer therapy. AstraZeneca subsequently acquired Fusion Pharmaceuticals for approximately $2.4 billion in 2024.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-02-13
Description

Acquisition of Investigational New Drug (IND) application for Phase 2 clinical trial evaluating 225Ac-PSMA I&T, a targeted alpha therapy for metastatic castration-resistant prostate cancer.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-01-01
Description

Acquisition of IPN-1087, a small molecule targeting neurotensin receptor 1 (NTSR1), in 2021. Previously in Phase 1 as lutetium-177 radiopharmaceutical; now being developed as actinium-225 targeted alpha therapeutic FPI-2059.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2019-01-01
Description

Exclusive license to AVE1642 humanized antibody against IGF-1R for development as targeted alpha therapeutic FPI-1434. Previously in Phase I/II clinical trials.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2018-04-18
Description

Licensing agreement to utilize Isogenica's proprietary in vitro CIS Display technology for discovery, development and commercialisation of therapeutic products derived from polypeptide libraries for targeted alpha therapeutics.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2017-09-25
Description

Two licensing agreements for centyrin-based targeting molecules in combination with Fusion's labeling technologies. Centyrins are small proteins with high selectivity and specificity for cancer cell targeting.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Novartis commercializes PLUVICTO (177Lu-PSMA-617), the leading approved PSMA-targeted radioligand therapy for mCRPC, and is the principal direct competitor to Fusion's lead FPI-2265 alpha-emitting program.

TypeEmerging player
Description

Aktis Oncology is an emerging clinical-stage developer of alpha-emitting radiopharmaceuticals for solid tumors, sharing Fusion's TAT platform approach using Ac-225 and proprietary targeting chemistry.

TypeBroad incumbent
Description

Lilly acquired Point Biopharma and is investing heavily in radioligand therapy capabilities (including the BroadGBM and other partnerships), making it a strategic incumbent competitor for radiopharmaceutical talent, pipeline assets, and indications Fusion targets.

TypeDirect peer
Description

Telix develops and commercializes PSMA-targeted imaging (Illuccix) and is advancing alpha-emitting radioligand therapies, closely mirroring Fusion's theranostic and TAT positioning.

TypeDirect peer
Description

Lantheus markets PYLARIFY (Piflufolastat F-18) PSMA diagnostic imaging agent and acquired Point Biopharma to enter PSMA radioligand therapy, making it the closest comparable radiopharmaceutical platform with paired diagnostics and therapy.

TypeEmerging player
Description

Convergent is a clinical-stage company developing alpha-emitting radioligand therapies (notably Ac-225 based) for prostate cancer, representing an emerging direct competitor in the same modality and indication.

TypeDirect peer
Description

ITM is a clinical-to-commercial radiopharmaceutical platform developing both diagnostic and therapeutic radioligands across multiple targets, directly comparable to Fusion's Targeted Alpha Therapeutics platform.

TypeDirect peer
Description

Point Biopharma (acquired by Lantheus) developed PSMA-targeted radioligand therapies (PNT2002) competing in the same mCRPC indication as Fusion's FPI-2265 with similar targeting approach.

TypeBroad incumbent
Description

Bayer markets Xofigo (radium-223), the first approved alpha-emitting radiopharmaceutical for prostate cancer, providing direct therapeutic overlap and prior validation of alpha-emitter commercial viability.

TypeBroad incumbent
Description

RayzeBio, acquired by BMS, developed actinium-225-based radiopharmaceuticals for solid tumors, making it the most direct platform peer in targeted alpha therapy now backed by a global biopharma.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors21 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Fusion Pharmaceuticals

Targeted Alpha Therapeutics / Radiopharmaceuticalsfusionpharma.com

Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted alpha therapeutics (actinium-225 radiopharmaceuticals with proprietary Fast-Clear™ linkers) for cancers including prostate, lung, and gastrointestinal tumors, now a wholly-owned AstraZeneca subsidiary.

What Fusion Pharmaceuticals does

Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company developing next-generation targeted alpha therapeutics (TAT) for the treatment of cancer, built around actinium-225 alpha-emitting isotopes combined with proprietary Fast-Clear™ linker technology. The platform pairs medical isotopes with cancer-targeting molecules (antibodies, small molecules, centyrins) to deliver lethal double-stranded DNA breaks selectively to tumor cells while sparing healthy tissue, with three distinct mechanisms of action: direct DNA damage, bystander effect, and alpha-particle-mediated immune activation.

The company's pipeline includes FPI-2265 (lead asset, 225Ac-PSMA I&T in Phase 2 TATCIST for metastatic castration-resistant prostate cancer, including both PSMA-naïve and 177Lu-PSMA-pretreated patients), FPI-1434 (Phase 1 anti-IGF-1R radioimmunoconjugate for solid tumors with imaging analogue FPI-1547), FPI-2059 (anti-NTSR1 acquired from Ipsen for pancreatic, colorectal, and gastric cancers), and FPI-2068 (anti-EGFR/cMET co-developed with AstraZeneca, FDA IND clearance April 2023). Preclinical assets include FPI-1966 (FGFR3 for bladder cancer) and FPI-1848 (TEM-1 for sarcoma).

Fusion was founded in 2015 as a spin-out from McMaster University's Centre for Probe Development and Commercialization (CPDC), headquartered in Hamilton, Ontario, with US operations in Boston, MA. The company raised approximately $231M in equity across Series A, Series B, a CPPIB commitment, and a 2023 private placement before being acquired by AstraZeneca in June 2024 for approximately $2.4 billion. Pre-acquisition business model was research-driven with no commercial revenue; future monetization was expected through direct commercialization (specialty/hospital pharmacy distribution for short-half-life alpha radiopharmaceuticals) and strategic partnerships.

Fusion Pharmaceuticals firmographics

Firmographics
Name
Fusion Pharmaceuticals
Legal name
Fusion Pharmaceuticals Inc.
Website
https://fusionpharma.com
Company type
Private
Founded year
2015
Operating status
Acquired
Headcount range
51–100 employees
Short description
Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted alpha therapeutics (actinium-225 radiopharmaceuticals with proprietary Fast-Clear™ linkers) for cancers including prostate, lung, and gastrointestinal tumors, now a wholly-owned AstraZeneca subsidiary.
Ownership category
akta.pro rank

Fusion Pharmaceuticals industry classification

Industry
Product category
Targeted Alpha Therapeutics / Radiopharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAG
Nuclear Medicine Imaging Agents & Kits (Cold Kits/Precursors)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

Keywords

  • Targeted alpha therapeutics
  • Radiopharmaceutical development
  • Cancer precision medicine
  • Actinium-225 isotopes
  • Clinical oncology pipeline

Where Fusion Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Hamilton
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

Fusion Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Radiopharmaceutical Drug Development and Commercialization: Pre-revenue clinical-stage company developing targeted alpha therapeutics pipeline. Revenue expected from future drug commercialization upon regulatory approval. Multiple candidates in clinical development targeting prostate cancer and solid tumors.

Go-to-market motion1 record

Marketing channels3 records

Fusion Pharmaceuticals product offering

Product offering

Core offering

Fusion Pharmaceuticals develops clinical-stage targeted alpha therapeutics (TAT) that use actinium-225 alpha-emitting isotopes conjugated to tumor-targeting molecules (antibodies, small molecules) via its proprietary Fast-Clear™ linker technology. Lead asset FPI-2265 is in Phase 2 for metastatic castration-resistant prostate cancer, with additional candidates targeting IGF-1R, NTSR1, EGFR/cMET, FGFR3, and TEM-1 expressing tumors.

Product overview

Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company developing next-generation radiopharmaceuticals as precision medicines for cancer treatment. The company's portfolio consists of multiple targeted alpha therapeutics (TAT) using actinium-225, built on its proprietary Fast-Clear linker technology platform. Key products include FPI-2265 (lead program, Phase 2 for mCRPC), FPI-1434 (Phase 1 for IGF-1R expressing solid tumors), FPI-2059 (NTSR1-targeted for solid tumors), FPI-2068 (EGFR/cMET-targeting), and several preclinical candidates (FPI-1966, FPI-1848). The Fast-Clear linker technology differentiates the platform by promoting rapid excretion of unbound isotopes to improve safety and expand the therapeutic window.

Differentiator

Problem solved

Functional benefit

Products and services

  • FPI-2265 (225Ac-PSMA I&T) Alpha-emitting radiopharmaceutical using actinium-225 conjugated to a PSMA-targeting small molecule, in Phase 2 for metastatic castration-resistant prostate cancer (mCRPC). Built on Fusion's Fast-Clear linker technology.
  • FPI-1434 Targeted alpha radioimmunoconjugate consisting of anti-IGF-1R humanized monoclonal antibody, Fusion's Fast-Clear linker, a bifunctional chelate, and actinium-225. In Phase 1 for solid tumors expressing IGF-1R (non-small cell lung, prostate, sarcomas, breast).
  • FPI-2059 Small-molecule targeted alpha therapy combining Ipsen's IPN-1087 NTSR1 ligand with actinium-225 for solid tumors overexpressing neurotensin receptor 1 (NTSR1), including pancreatic ductal adenocarcinoma, colorectal cancer, and gastric cancers.
  • FPI-2068 Anti-EGFR/cMET alpha-particle emitting radioimmunoconjugate co-developed with AstraZeneca for cancer therapy; FDA IND cleared April 2023.
  • FPI-1966 FGFR3-targeted alpha therapeutic using actinium-225; preclinical-stage asset for bladder cancer.
  • FPI-1848 TEM-1-targeted alpha therapeutic using actinium-225; preclinical-stage asset for sarcoma.
  • FPI-1547 Imaging/diagnostic analogue of FPI-1434 using indium-111 (111In) in place of actinium-225, used for patient selection and quantification of IGF-1R-expressing tumors prior to therapy.

Quantifiable outcome

  • Phase 2 TATCIST trial evaluating FPI-2265 (225Ac-PSMA I&T) in mCRPC with initial data expected in early 2024
  • +1 more outcomes

Companies that use Fusion Pharmaceuticals

Customer profile

Segments3 records

Ideal customer profiles2 records

Fusion Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Fusion Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered flagship and core.

  • AstraZenecaflagshipStrategic or Co-development Partner · 1 April 2023Joint development of FPI-2068, a novel anti-EGFR/cMET alpha-particle emitting radioimmunoconjugate for cancer therapy. AstraZeneca subsequently acquired Fusion Pharmaceuticals for approximately $2.4 billion in 2024.
  • RadioMedixcoreTechnology or Integration · 13 February 2023Acquisition of Investigational New Drug (IND) application for Phase 2 clinical trial evaluating 225Ac-PSMA I&T, a targeted alpha therapy for metastatic castration-resistant prostate cancer.
  • IpsencoreTechnology or Integration · 1 January 2021Acquisition of IPN-1087, a small molecule targeting neurotensin receptor 1 (NTSR1), in 2021. Previously in Phase 1 as lutetium-177 radiopharmaceutical; now being developed as actinium-225 targeted alpha therapeutic FPI-2059.
  • ImmunoGencoreTechnology or Integration · 1 January 2019Exclusive license to AVE1642 humanized antibody against IGF-1R for development as targeted alpha therapeutic FPI-1434. Previously in Phase I/II clinical trials.
  • IsogenicacoreTechnology or Integration · 18 April 2018Licensing agreement to utilize Isogenica's proprietary in vitro CIS Display technology for discovery, development and commercialisation of therapeutic products derived from polypeptide libraries for targeted alpha therapeutics.
  • Janssen BiotechcoreTechnology or Integration · 25 September 2017Two licensing agreements for centyrin-based targeting molecules in combination with Fusion's labeling technologies. Centyrins are small proteins with high selectivity and specificity for cancer cell targeting.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Fusion Pharmaceuticals competitors and assessment

Company assessment

Broad incumbents

  • Novartis: Novartis commercializes PLUVICTO (177Lu-PSMA-617), the leading approved PSMA-targeted radioligand therapy for mCRPC, and is the principal direct competitor to Fusion's lead FPI-2265 alpha-emitting program.
  • Eli Lilly: Lilly acquired Point Biopharma and is investing heavily in radioligand therapy capabilities (including the BroadGBM and other partnerships), making it a strategic incumbent competitor for radiopharmaceutical talent, pipeline assets, and indications Fusion targets.
  • Bayer: Bayer markets Xofigo (radium-223), the first approved alpha-emitting radiopharmaceutical for prostate cancer, providing direct therapeutic overlap and prior validation of alpha-emitter commercial viability.
  • RayzeBio (Bristol Myers Squibb): RayzeBio, acquired by BMS, developed actinium-225-based radiopharmaceuticals for solid tumors, making it the most direct platform peer in targeted alpha therapy now backed by a global biopharma.

Emerging players

  • Aktis Oncology: Aktis Oncology is an emerging clinical-stage developer of alpha-emitting radiopharmaceuticals for solid tumors, sharing Fusion's TAT platform approach using Ac-225 and proprietary targeting chemistry.
  • Convergent Therapeutics: Convergent is a clinical-stage company developing alpha-emitting radioligand therapies (notably Ac-225 based) for prostate cancer, representing an emerging direct competitor in the same modality and indication.

Direct peers

  • Telix Pharmaceuticals: Telix develops and commercializes PSMA-targeted imaging (Illuccix) and is advancing alpha-emitting radioligand therapies, closely mirroring Fusion's theranostic and TAT positioning.
  • Lantheus Holdings: Lantheus markets PYLARIFY (Piflufolastat F-18) PSMA diagnostic imaging agent and acquired Point Biopharma to enter PSMA radioligand therapy, making it the closest comparable radiopharmaceutical platform with paired diagnostics and therapy.
  • ITM Radiopharma: ITM is a clinical-to-commercial radiopharmaceutical platform developing both diagnostic and therapeutic radioligands across multiple targets, directly comparable to Fusion's Targeted Alpha Therapeutics platform.
  • Point Biopharma: Point Biopharma (acquired by Lantheus) developed PSMA-targeted radioligand therapies (PNT2002) competing in the same mCRPC indication as Fusion's FPI-2265 with similar targeting approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Fusion Pharmaceuticals social profiles

Digital presence

Fusion Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Fusion Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles8 records

Fusion Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors21 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Fusion Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fusion Pharmaceuticals

What does Fusion Pharmaceuticals do?

Fusion Pharmaceuticals develops clinical-stage targeted alpha therapeutics (TAT) that use actinium-225 alpha-emitting isotopes conjugated to tumor-targeting molecules (antibodies, small molecules) via its proprietary Fast-Clear™ linker technology. Lead asset FPI-2265 is in Phase 2 for metastatic castration-resistant prostate cancer, with additional candidates targeting IGF-1R, NTSR1, EGFR/cMET, FGFR3, and TEM-1 expressing tumors.

Is Fusion Pharmaceuticals a public or private company?

Fusion Pharmaceuticals is a private company. It is classified as corporate owned and is currently acquired.

When was Fusion Pharmaceuticals founded?

Fusion Pharmaceuticals was founded in 2015. It employs 51 to 100 people.

Where is Fusion Pharmaceuticals based?

Fusion Pharmaceuticals is headquartered in Hamilton, Canada, in the North America region.

How does Fusion Pharmaceuticals make money?

One revenue line is on record: radiopharmaceutical Drug Development and Commercialization.

Who are Fusion Pharmaceuticals's main competitors?

Broad incumbents on record are Novartis, Eli Lilly, Bayer and RayzeBio (Bristol Myers Squibb). Emerging players are Aktis Oncology and Convergent Therapeutics. Direct peers are Telix Pharmaceuticals, Lantheus Holdings, ITM Radiopharma and Point Biopharma.

Does Fusion Pharmaceuticals have an API?

No public API is recorded for Fusion Pharmaceuticals.

What industry is Fusion Pharmaceuticals in?

Fusion Pharmaceuticals's product category is Targeted Alpha Therapeutics / Radiopharmaceuticals. Its primary akta.pro industry code is HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy), with a secondary code of HLAIAGAC, Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireGlobal Targeted Alpha Therapy Market Size, Clinical Trials, Regulatory Approvals, and Technology Forecast to 2030 | Precision Oncology Pipelines and Isotope Innovation Fuel GrowthResearchAndMarkets.com released a report on the global targeted alpha therapy market, covering clinical trials, regulatory approvals, and technology. The report notes over 30 drugs in clinical trials, with a Phase II trial reporting response rates up to 60% for a lead-212 compound. It also highlights M&A activity, including AstraZeneca's acquisition of Fusion Pharmaceuticals.PR.comBIX 2026 to Spotlight the Future of Stem Cell and Global Biopharma M&ABIX 2026, Korea's leading bio and pharmaceutical convention, announced keynote speakers Temple and Stuart Cable, focusing on stem cells for nervous system diseases and biopharma M&A trends. Pre-registration is open through August 31 with early-bird discounts.NewsfileDefence Therapeutics Strengthens Radiopharmaceutical Leadership with Appointment of Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical ProgramsDefence Therapeutics appointed Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical Programs to strengthen its leadership in developing next-generation precision oncology therapeutics. The appointment follows the recent hiring of President and CEO Dr. Amie Phinney and the opening of a new office at McMaster Innovation Park, positioning the company for accelerated development of its Accum® platform. Dr. Simms brings over 20 years of experience from previous roles at Fusion Pharmaceuticals and Abdera Therapeutics.BioSpaceDefence Therapeutics Strengthens Radiopharmaceutical Leadership with Appointment of Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical ProgramsDefence Therapeutics appointed Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical Programs. He brings over 20 years of experience, including roles at Fusion Pharmaceuticals, which was acquired by AstraZeneca for about $2 billion. His immediate priority is selecting a lead radiopharmaceutical candidate and advancing it through preclinical characterization.TaiwansunCurium strikes up to $8 billion deal for LantheusCurium agreed to acquire Lantheus Holdings in a deal worth up to $8 billion, announced August 3. Shareholders receive $102.50 per share in cash plus up to $12 more if sales targets are met by 2030, a 14.9% premium over the last closing price. The deal is expected to close in the first half of 2027.European Biotechnology8 European VC firms to watch in 2026Eight European VC firms are profiled for 2026, including Jeito Capital, Sofinnova Partners, and Medicxi, with fund sizes and recent exits. The list highlights firms that closed new biotech funds in the past year, such as Jeito II at $1.2 billion and Medicxi V at €500 million. The firms are positioned as shaping the continent's investment landscape amid tighter capital.openPR.comKey Factors and Emerging Trends Shaping the Radiation Toxicity Treatment Market LandscapeThe radiation toxicity treatment market is projected to grow to $5.37 billion by 2030, with a compound annual growth rate of 6.1%, driven by increased investments in radiation countermeasures, rising demand for fast-acting radiation therapies, and personalized toxicity management approaches. In June 2024, AstraZeneca Plc completed its acquisition of Fusion Pharmaceuticals Inc. for $2.5 billion to strengthen its radiopharmaceutical portfolio, while in December 2023, Coherus BioSciences received FDA approval for UDENYCA ONBODY, an innovative on-body injector for chemotherapy-related infection prevention.openPR.comKey Players and Competitive Dynamics in the Metastatic Prostate Cancer MarketThe metastatic prostate cancer market is projected to reach $13.16 billion by 2030, growing at a compound annual growth rate of 8.3%, driven by advancements in immunotherapy, radiopharmaceutical therapies, and personalized cancer treatments. AstraZeneca PLC acquired Fusion Pharmaceuticals in June 2024 for $2.4 billion to strengthen its radioconjugate platform for targeted cancer therapies, specifically focusing on metastatic castration-resistant prostate cancer. Additionally, Intuitive Surgical Inc. received FDA clearance in April 2025 for its SureForm 45 stapler designed for use with the da Vinci SP surgical system.GlobeNewswireTargeted Alpha Therapy Market Landscape Report 2026-2030: Clinical Trials Insights on 30 Drugs - Size, Regulatory Approvals, Proprietary Technologies, Therapeutic ApplicationsResearchAndMarkets.com announced the release of a comprehensive market report on Targeted Alpha Therapy (TAT) covering over 30 drugs in clinical trials, proprietary technologies, and therapeutic applications for cancer treatment through 2030. The global TAT market is experiencing rapid growth driven by clinical advancement of alpha emitters including Actinium-225, Astatine-211, and Lead-212, with notable M&A activity including AstraZeneca's acquisition of Fusion Pharmaceuticals and Bristol Myers Squibb's acquisition of RayzeBio. The report identifies strategic partnerships such as NAYA Therapeutics' alliance with Alpha Nuclide in China to manufacture Astatine-211, highlighting the importance of scalable isotope production and international logistics.NusDrug Targets, Indications, PatentsMajor pharmaceutical companies including AstraZeneca, Bristol Myers Squibb, Eli Lilly and Novartis are racing to compete in the radiopharmaceutical market, projected to reach $13-16 billion by 2033, by advancing actinium-225-based alpha-emitting therapies for cancer treatment. AstraZeneca secured entry through its up to $2.4 billion acquisition of Fusion Pharmaceuticals in March 2024, gaining lead asset FPI-2265 in Phase II for metastatic prostate cancer and AZD2068 in Phase I for solid tumors; BMS made the larger move with its $4.1 billion acquisition of RayzeBio in December 2023; and Lilly acquired Point Biopharma for $1.4 billion in October 2023. Novartis currently dominates with two FDA-approved radiopharma products, Lutathera and Pluvicto, which generated over $2.1 billion in combined 2024 sales, and recently won a label expansion pushing Pluvicto into an earlier prostate cancer treatment setting.